$NVCR
NovoCure Ltd Stock $nvcr

$nvcr Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000164511324000013 Filed on May 02, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$150.4M	$138.5M
YoY Change	19.28%	13.36%
Cost Of Revenue	$34.65M	$33.69M
YoY Change	1.87%	13.76%
Gross Profit	$115.7M	$104.8M
YoY Change	25.72%	13.23%
Gross Profit Margin	76.95%	75.68%
Selling, General & Admin	$94.33M	$94.74M
YoY Change	-4.98%	1.74%
% of Gross Profit	81.53%	90.38%
Research & Development	$54.96M	$51.60M
YoY Change	-0.85%	-13.58%
% of Gross Profit	47.5%	49.23%
Depreciation & Amortization	$2.858M	$2.815M
YoY Change	5.03%	3.42%
% of Gross Profit	2.47%	2.69%
Operating Expenses	$149.3M	$146.3M
YoY Change	-3.5%	-4.24%
Operating Profit	-$33.58M	-$41.52M
YoY Change	-46.41%	-31.09%
Interest Expense	$10.85M	$9.878M
YoY Change	23.93%	7.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$22.73M	-$31.64M
YoY Change	-57.83%	-38.05%
Income Tax	$10.65M	$7.118M
% Of Pretax Income
Net Earnings	-$33.38M	-$38.76M
YoY Change	-41.87%	-26.95%
Net Earnings / Revenue	-22.2%	-27.98%
Basic Earnings Per Share	-$0.31	-$0.36
Diluted Earnings Per Share	-$0.31	-$0.36
COMMON SHARES
Basic Shares Outstanding	107.6M shares	107.1M shares
Diluted Shares Outstanding	107.7M shares	107.3M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$951.2M	$870.1M
YoY Change	1.1%	-9.17%
Cash & Equivalents	$164.8M	$453.8M
Short-Term Investments	$788.4M	$439.6M
Other Short-Term Assets	$3.647M	$3.600M
YoY Change	606.78%	432.54%
Inventory	$40.44M	$42.39M
Prepaid Expenses
Receivables	$64.70M	$65.09M
Other Receivables	$32.86M	$21.48M
Total Short-Term Assets	$1.093B	$1.003B
YoY Change	2.57%	-7.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.48M	$58.92M
YoY Change	-15.8%	61.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.06M	$14.90M
YoY Change	-17.22%	33.66%
Total Long-Term Assets	$119.3M	$118.7M
YoY Change	27.6%	39.11%
TOTAL ASSETS
Total Short-Term Assets	$1.093B	$1.003B
Total Long-Term Assets	$119.3M	$118.7M
Total Assets	$1.212B	$1.121B
YoY Change	4.59%	-4.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$90.17M	$84.32M
YoY Change	9.25%	3.49%
Accrued Expenses
YoY Change
Deferred Revenue	$15.61M	$15.87M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$169.2M	$160.2M
YoY Change	12.72%	7.7%
LONG-TERM LIABILITIES
Long-Term Debt	$653.5M	$569.7M
YoY Change	15.22%	0.59%
Other Long-Term Liabilities	$18.00K	$18.00K
YoY Change	-99.93%	-86.76%
Total Long-Term Liabilities	$681.2M	$601.8M
YoY Change	14.83%	1.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$169.2M	$160.2M
Total Long-Term Liabilities	$681.2M	$601.8M
Total Liabilities	$850.4M	$762.1M
YoY Change	14.41%	2.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.058B	-$1.024B
YoY Change	18.98%	23.18%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$361.8M	$359.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.212B	$1.121B
YoY Change	4.59%	-4.51%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$33.38M	-$38.76M
YoY Change	-41.87%	-26.95%
Depreciation, Depletion And Amortization	$2.858M	$2.815M
YoY Change	5.03%	3.42%
Cash From Operating Activities	-$1.720M	-$31.57M
YoY Change	-92.44%	88.76%
INVESTING ACTIVITIES
Capital Expenditures	$11.45M	$11.78M
YoY Change	65.14%	93.56%
Acquisitions
YoY Change
Other Investing Activities	-$363.0M	$258.0M
YoY Change	5110.94%	191.94%
Cash From Investing Activities	-$374.4M	$246.2M
YoY Change	2594.39%	199.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$12.91M	$0.00
YoY Change	430333.33%	-100.0%
Cash From Financing Activities	$87.32M	$213.0K
YoY Change	1063.92%	-95.91%
NET CHANGE
Cash From Operating Activities	-$1.720M	-$31.57M
Cash From Investing Activities	-$374.4M	$246.2M
Cash From Financing Activities	$87.32M	$213.0K
Net Change In Cash	-$288.9M	$214.8M
YoY Change	891.76%	203.37%
FREE CASH FLOW
Cash From Operating Activities	-$1.720M	-$31.57M
Capital Expenditures	$11.45M	$11.78M
Free Cash Flow	-$13.17M	-$43.36M
YoY Change	-55.62%	90.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	569652000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	568822000	usd
CY2024Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25608000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27420000	usd
CY2024Q1	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	6566000	usd
CY2023Q4	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	8258000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	601844000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	604518000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	762074000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	783633000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107603774	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107603774	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1387765000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1353468000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4147000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5469000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1024263000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-985503000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	359355000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	362496000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1121429000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1146129000	usd
CY2024Q1	us-gaap	Revenues Revenues	138503000	usd
CY2023Q1	us-gaap	Revenues Revenues	122182000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	33689000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	29614000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	128280000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	104814000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	92568000	usd
CY2023	us-gaap	Gross Profit GrossProfit	381058000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51598000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59704000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	223062000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	55206000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	51169000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	226809000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39530000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41944000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	164057000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	146334000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	152817000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	613928000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-41520000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-60249000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-232870000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	9878000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	9169000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	41130000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31642000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51080000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-191740000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7118000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1981000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15303000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107266198	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107266198	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105667072	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105667072	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106391178	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106391178	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4072000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18245000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-327000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	300000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1473000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	357000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	445000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-1649000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	915000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	4954000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37438000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53319000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-210079000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	362496000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34084000	usd
CY2024Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	213000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1322000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	359355000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441170000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39084000	usd
CY2023Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	5211000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-258000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	432146000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2815000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2722000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10969000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1622000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1120000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-95000	usd
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	194000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	126000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	493000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	34084000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	39084000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	115608000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-613000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	127000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-161000	usd
CY2024Q1	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	3275000	usd
CY2023Q1	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	-14511000	usd
CY2023	nvcr	Increase Decrease In Accounts Receivables And Prepaid Expenses IncreaseDecreaseInAccountsReceivablesAndPrepaidExpenses	-29414000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-5381000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-4056000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-23084000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4650000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2718000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8919000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1174000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10464000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14869000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1534000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1765000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3158000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-9781000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31574000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16727000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73336000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11784000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6088000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27093000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	258000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	326287000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	1214982000	usd
CY2024Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	237912000	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1003741000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	246216000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	82287000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	184148000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4416000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	213000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5211000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11381000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	213000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5204000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15787000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-56000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	214799000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70805000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	126730000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242564000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115834000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115834000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	457363000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186639000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242564000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2914000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1712000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	13665000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	6000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	453763000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185963000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	240821000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3600000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	676000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3451000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18063000	usd
CY2024Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1062000	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1743000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	457363000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186639000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	242564000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	282000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	520621000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	520326000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesAmortizedCost	910616000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	554000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	259000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Fair Value CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesFairValue	910911000	usd
CY2023Q4	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecurities	910616000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1714000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Concentration Risks. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally and the total value invested at any one institution is limited pursuant to the Company's investment policy. These investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand according to the terms of the securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's trade receivables are due from numerous governments and federal and state agencies that are paid from their respective budgets, and from hundreds of health insurance companies. The Company does not believe that there are significant default risks associated with these governments, agencies and health insurance companies based upon the Company's historical experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></div>
CY2024Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	433278000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	369000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	5000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	433642000	usd
CY2024Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	433278000	usd
CY2024Q1	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesAmortizedCost	870147000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	369000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	5000	usd
CY2024Q1	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities Fair Value CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecuritiesFairValue	870511000	usd
CY2024Q1	nvcr	Cash Cash Equivalents Available For Sale And Held To Maturity Debt Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturityDebtSecurities	870147000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	520326000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	554000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	259000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10174000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10265000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11934000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9796000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	20283000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	18091000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	42391000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38152000	usd
CY2024Q1	us-gaap	Deposits Assets DepositsAssets	2798000	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	2848000	usd
CY2024Q1	us-gaap	Contractual Obligation ContractualObligation	3157000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	3216000	usd
CY2024Q1	us-gaap	Revenues Revenues	138503000	usd
CY2023Q1	us-gaap	Revenues Revenues	122182000	usd
CY2023	us-gaap	Revenues Revenues	509338000	usd
CY2024Q1	us-gaap	Revenues Revenues	138503000	usd
CY2023Q1	us-gaap	Revenues Revenues	122182000	usd
CY2023	us-gaap	Revenues Revenues	509338000	usd
CY2024Q1	nvcr	Accounts Receivable Excluding Unbilled Receivables AccountsReceivableExcludingUnbilledReceivables	60401000	usd
CY2023Q4	nvcr	Accounts Receivable Excluding Unbilled Receivables AccountsReceivableExcludingUnbilledReceivables	56970000	usd
CY2024Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4690000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4251000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15870000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16224000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	16224000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18028000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	18028000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8539507	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.07
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3456485	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.35
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26547	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.70
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	180377	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	58.72
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11789068	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.61
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6990097	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	34.67
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34084000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39084000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115608000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-38760000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53061000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-207043000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107266198	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105667072	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106391178	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12721020	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7543657	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8535785	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	70828000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	62863000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	200	employee
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	2031000	usd
CY2023	us-gaap	Restructuring Costs RestructuringCosts	6231000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	2031000	usd
CY2023	us-gaap	Restructuring Costs RestructuringCosts	6231000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	5128000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2753000	usd
CY2024Q1	nvcr	Employee Benefit And Share Based Payment Arrangement Reversal Of Accrual EmployeeBenefitAndShareBasedPaymentArrangementReversalOfAccrual	369000	usd
CY2023	nvcr	Employee Benefit And Share Based Payment Arrangement Reversal Of Accrual EmployeeBenefitAndShareBasedPaymentArrangementReversalOfAccrual	3041000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	1661000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	9313000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001645113-24-000013-index-headers.html	Edgar Link	pending
0001645113-24-000013-index.html	Edgar Link	pending
0001645113-24-000013.txt	Edgar Link	pending
0001645113-24-000013-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvcr-20240331.htm	Edgar Link	pending
nvcr-20240331.xsd	Edgar Link	pending
nvcr-20240331xexx311.htm	Edgar Link	pending
nvcr-20240331xexx312.htm	Edgar Link	pending
nvcr-20240331xexx321.htm	Edgar Link	pending
nvcr-20240331xexx322.htm	Edgar Link	pending
nvcr-20240331_g1.jpg	Edgar Link	pending
pharmakon-novocuresarlxx.htm	Edgar Link	pending
pharmakon-novocuresarlxx001.jpg	Edgar Link	pending
pharmakon-novocuresarlxx002.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvcr-20240331_cal.xml	Edgar Link	unprocessable
nvcr-20240331_lab.xml	Edgar Link	unprocessable
nvcr-20240331_pre.xml	Edgar Link	unprocessable
nvcr-20240331_htm.xml	Edgar Link	completed
pharmakon-novocuresarlxx003.jpg	Edgar Link	pending
pharmakon-novocuresarlxx004.jpg	Edgar Link	pending
pharmakon-novocuresarlxx005.jpg	Edgar Link	pending
pharmakon-novocuresarlxx006.jpg	Edgar Link	pending
pharmakon-novocuresarlxx007.jpg	Edgar Link	pending
pharmakon-novocuresarlxx008.jpg	Edgar Link	pending
pharmakon-novocuresarlxx009.jpg	Edgar Link	pending
pharmakon-novocuresarlxx010.jpg	Edgar Link	pending
pharmakon-novocuresarlxx011.jpg	Edgar Link	pending
pharmakon-novocuresarlxx012.jpg	Edgar Link	pending
pharmakon-novocuresarlxx013.jpg	Edgar Link	pending
pharmakon-novocuresarlxx014.jpg	Edgar Link	pending
pharmakon-novocuresarlxx015.jpg	Edgar Link	pending
pharmakon-novocuresarlxx016.jpg	Edgar Link	pending
pharmakon-novocuresarlxx017.jpg	Edgar Link	pending
pharmakon-novocuresarlxx018.jpg	Edgar Link	pending
pharmakon-novocuresarlxx019.jpg	Edgar Link	pending
pharmakon-novocuresarlxx020.jpg	Edgar Link	pending
pharmakon-novocuresarlxx021.jpg	Edgar Link	pending
pharmakon-novocuresarlxx022.jpg	Edgar Link	pending
pharmakon-novocuresarlxx023.jpg	Edgar Link	pending
pharmakon-novocuresarlxx024.jpg	Edgar Link	pending
pharmakon-novocuresarlxx025.jpg	Edgar Link	pending
pharmakon-novocuresarlxx026.jpg	Edgar Link	pending
pharmakon-novocuresarlxx027.jpg	Edgar Link	pending
pharmakon-novocuresarlxx028.jpg	Edgar Link	pending
pharmakon-novocuresarlxx029.jpg	Edgar Link	pending
pharmakon-novocuresarlxx030.jpg	Edgar Link	pending
pharmakon-novocuresarlxx031.jpg	Edgar Link	pending
pharmakon-novocuresarlxx032.jpg	Edgar Link	pending
pharmakon-novocuresarlxx033.jpg	Edgar Link	pending
pharmakon-novocuresarlxx034.jpg	Edgar Link	pending
pharmakon-novocuresarlxx035.jpg	Edgar Link	pending
pharmakon-novocuresarlxx036.jpg	Edgar Link	pending
pharmakon-novocuresarlxx037.jpg	Edgar Link	pending
pharmakon-novocuresarlxx038.jpg	Edgar Link	pending
pharmakon-novocuresarlxx039.jpg	Edgar Link	pending
pharmakon-novocuresarlxx040.jpg	Edgar Link	pending
pharmakon-novocuresarlxx041.jpg	Edgar Link	pending
pharmakon-novocuresarlxx042.jpg	Edgar Link	pending
pharmakon-novocuresarlxx043.jpg	Edgar Link	pending
pharmakon-novocuresarlxx044.jpg	Edgar Link	pending
pharmakon-novocuresarlxx045.jpg	Edgar Link	pending
pharmakon-novocuresarlxx046.jpg	Edgar Link	pending
pharmakon-novocuresarlxx047.jpg	Edgar Link	pending
pharmakon-novocuresarlxx048.jpg	Edgar Link	pending
pharmakon-novocuresarlxx049.jpg	Edgar Link	pending
pharmakon-novocuresarlxx050.jpg	Edgar Link	pending
pharmakon-novocuresarlxx051.jpg	Edgar Link	pending
pharmakon-novocuresarlxx052.jpg	Edgar Link	pending
pharmakon-novocuresarlxx053.jpg	Edgar Link	pending
pharmakon-novocuresarlxx054.jpg	Edgar Link	pending
pharmakon-novocuresarlxx055.jpg	Edgar Link	pending
pharmakon-novocuresarlxx056.jpg	Edgar Link	pending
pharmakon-novocuresarlxx057.jpg	Edgar Link	pending
pharmakon-novocuresarlxx058.jpg	Edgar Link	pending
pharmakon-novocuresarlxx059.jpg	Edgar Link	pending
pharmakon-novocuresarlxx060.jpg	Edgar Link	pending
pharmakon-novocuresarlxx061.jpg	Edgar Link	pending
pharmakon-novocuresarlxx062.jpg	Edgar Link	pending
pharmakon-novocuresarlxx063.jpg	Edgar Link	pending
pharmakon-novocuresarlxx064.jpg	Edgar Link	pending
pharmakon-novocuresarlxx065.jpg	Edgar Link	pending
pharmakon-novocuresarlxx066.jpg	Edgar Link	pending
pharmakon-novocuresarlxx067.jpg	Edgar Link	pending
pharmakon-novocuresarlxx068.jpg	Edgar Link	pending
pharmakon-novocuresarlxx069.jpg	Edgar Link	pending
pharmakon-novocuresarlxx070.jpg	Edgar Link	pending
pharmakon-novocuresarlxx071.jpg	Edgar Link	pending
pharmakon-novocuresarlxx072.jpg	Edgar Link	pending
pharmakon-novocuresarlxx073.jpg	Edgar Link	pending
pharmakon-novocuresarlxx074.jpg	Edgar Link	pending
pharmakon-novocuresarlxx075.jpg	Edgar Link	pending
pharmakon-novocuresarlxx076.jpg	Edgar Link	pending
pharmakon-novocuresarlxx077.jpg	Edgar Link	pending
pharmakon-novocuresarlxx078.jpg	Edgar Link	pending
pharmakon-novocuresarlxx079.jpg	Edgar Link	pending
pharmakon-novocuresarlxx080.jpg	Edgar Link	pending
pharmakon-novocuresarlxx081.jpg	Edgar Link	pending
pharmakon-novocuresarlxx082.jpg	Edgar Link	pending
pharmakon-novocuresarlxx083.jpg	Edgar Link	pending
pharmakon-novocuresarlxx084.jpg	Edgar Link	pending
pharmakon-novocuresarlxx085.jpg	Edgar Link	pending
pharmakon-novocuresarlxx086.jpg	Edgar Link	pending
pharmakon-novocuresarlxx087.jpg	Edgar Link	pending
pharmakon-novocuresarlxx088.jpg	Edgar Link	pending
pharmakon-novocuresarlxx089.jpg	Edgar Link	pending
pharmakon-novocuresarlxx090.jpg	Edgar Link	pending
pharmakon-novocuresarlxx091.jpg	Edgar Link	pending
pharmakon-novocuresarlxx092.jpg	Edgar Link	pending
pharmakon-novocuresarlxx093.jpg	Edgar Link	pending
pharmakon-novocuresarlxx094.jpg	Edgar Link	pending
pharmakon-novocuresarlxx095.jpg	Edgar Link	pending
pharmakon-novocuresarlxx096.jpg	Edgar Link	pending
pharmakon-novocuresarlxx097.jpg	Edgar Link	pending
pharmakon-novocuresarlxx098.jpg	Edgar Link	pending
pharmakon-novocuresarlxx099.jpg	Edgar Link	pending
pharmakon-novocuresarlxx100.jpg	Edgar Link	pending
pharmakon-novocuresarlxx101.jpg	Edgar Link	pending
pharmakon-novocuresarlxx102.jpg	Edgar Link	pending
pharmakon-novocuresarlxx103.jpg	Edgar Link	pending
pharmakon-novocuresarlxx104.jpg	Edgar Link	pending
pharmakon-novocuresarlxx105.jpg	Edgar Link	pending
pharmakon-novocuresarlxx106.jpg	Edgar Link	pending
pharmakon-novocuresarlxx107.jpg	Edgar Link	pending
pharmakon-novocuresarlxx108.jpg	Edgar Link	pending
pharmakon-novocuresarlxx109.jpg	Edgar Link	pending
pharmakon-novocuresarlxx110.jpg	Edgar Link	pending
pharmakon-novocuresarlxx111.jpg	Edgar Link	pending
pharmakon-novocuresarlxx112.jpg	Edgar Link	pending
pharmakon-novocuresarlxx113.jpg	Edgar Link	pending
pharmakon-novocuresarlxx114.jpg	Edgar Link	pending
pharmakon-novocuresarlxx115.jpg	Edgar Link	pending
pharmakon-novocuresarlxx116.jpg	Edgar Link	pending
pharmakon-novocuresarlxx117.jpg	Edgar Link	pending
pharmakon-novocuresarlxx118.jpg	Edgar Link	pending
pharmakon-novocuresarlxx119.jpg	Edgar Link	pending
pharmakon-novocuresarlxx120.jpg	Edgar Link	pending
pharmakon-novocuresarlxx121.jpg	Edgar Link	pending
pharmakon-novocuresarlxx122.jpg	Edgar Link	pending
pharmakon-novocuresarlxx123.jpg	Edgar Link	pending
pharmakon-novocuresarlxx124.jpg	Edgar Link	pending
pharmakon-novocuresarlxx125.jpg	Edgar Link	pending
pharmakon-novocuresarlxx126.jpg	Edgar Link	pending
pharmakon-novocuresarlxx127.jpg	Edgar Link	pending
pharmakon-novocuresarlxx128.jpg	Edgar Link	pending
pharmakon-novocuresarlxx129.jpg	Edgar Link	pending
pharmakon-novocuresarlxx130.jpg	Edgar Link	pending
pharmakon-novocuresarlxx131.jpg	Edgar Link	pending
pharmakon-novocuresarlxx132.jpg	Edgar Link	pending
pharmakon-novocuresarlxx133.jpg	Edgar Link	pending
pharmakon-novocuresarlxx134.jpg	Edgar Link	pending
pharmakon-novocuresarlxx135.jpg	Edgar Link	pending
pharmakon-novocuresarlxx136.jpg	Edgar Link	pending
pharmakon-novocuresarlxx137.jpg	Edgar Link	pending
pharmakon-novocuresarlxx138.jpg	Edgar Link	pending
pharmakon-novocuresarlxx139.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nvcr-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVCR
NovoCure Ltd Stock $nvcr

2024 Q2 Form 10-Q Financial Statement

#000164511324000013 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR NovoCure Ltd Stock $nvcr

2024 Q2 Form 10-Q Financial Statement

#000164511324000013 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR
NovoCure Ltd Stock $nvcr